Improvement of Endothelial Function with Metformin and Rosiglitazone Treatment in Women with Polycystic Ovary Syndrome

    July 2008 in “ European journal of endocrinology ”
    Mojca Jensterle, Miran Šebeštjen, Andrej Janez, Janez Prezelj, Tomaz Kocjan, Irena Keber, Marija Pfeifer
    New to Metformin? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that a 6-month treatment with either metformin or rosiglitazone significantly improved endothelial function in young women with PCOS without any one drug being superior. Our plain-language summary of this paper — not a Tressless recommendation.
    In the 2008 study involving 26 women with polycystic ovary syndrome (PCOS), metformin (MET) and rosiglitazone (ROSI) treatments over 6 months were found to significantly improve endothelial function, as indicated by increased flow-mediated dilation (FMD) of the brachial artery. MET treatment also resulted in a significant decrease in insulin resistance, serum total and free testosterone levels, and an increase in menstrual bleeding frequency. The study concluded that MET and ROSI could markedly improve endothelial function in young PCOS patients, potentially reversing early-stage atherosclerotic processes, with MET providing additional benefits in reducing insulin resistance and testosterone levels.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results